Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Dementia01:30

Dementia

672
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
672
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Amyloid Fibrils03:03

Amyloid Fibrils

12.9K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.9K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.9K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human microglial transitions at the Aβ-tau inflection point associate with divergent pathways to dementia and resilience.

Nature medicine·2026
Same author

Tracking the turning point in Alzheimer's disease.

Science (New York, N.Y.)·2026
Same author

Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ42 fibrils with cross-seeding activity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Aβ plaques induce local pre-synaptic toxicity in human iPSC-derived neuron xenografts.

Stem cell reports·2026
Same author

The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia.

Nature neuroscience·2025
Same author

Phagocytes as Plaque Catalysts: Human Macrophages Actively Generate Pathogenic Aβ42 Fibrils with Seeding and Cross-Seeding Potency.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Mar 25, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K

Alzheimer's disease.

Philip Scheltens1, Kaj Blennow2, Monique M B Breteler3

  • 1Department of Neurology & Alzheimer Center, VU University Medical Center, Amsterdam, Netherlands.

Lancet (London, England)
|February 28, 2016
PubMed
Summary

Research into Alzheimer's disease is evolving beyond the amyloid hypothesis, exploring complex interactions and early disease stages. Future treatments will likely combine targeted therapies with lifestyle interventions for comprehensive brain health management.

More Related Videos

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.9K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.6K

Related Experiment Videos

Last Updated: Mar 25, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.9K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.6K

Area of Science:

  • Neurology
  • Neuroscience
  • Biomarker Research

Background:

  • Global dementia prevalence is rising, yet Western incidence may be declining due to improved vascular care and brain health.
  • The traditional amyloid hypothesis for Alzheimer's disease (AD) is being challenged by a more complex understanding involving interacting factors.
  • Established biomarkers include amyloid β42 and tau; emerging candidates are amyloid β oligomers and synaptic markers.

Purpose of the Study:

  • To review key developments in Alzheimer's disease research.
  • To discuss the shift towards understanding preclinical AD and the interaction of various disease factors.
  • To explore advancements in diagnostic and therapeutic strategies for AD.

Main Methods:

  • Review of current literature on Alzheimer's disease pathogenesis, biomarkers, and imaging.
  • Analysis of emerging research trends, including preclinical AD and lifestyle interventions.
  • Discussion of established and novel diagnostic techniques like MRI, PET scans, and fluid biomarkers.

Main Results:

  • Research is moving beyond linear causality, acknowledging interactions between age, protective, and disease-promoting factors.
  • Amyloid PET and Tau PET show promise for clinical application, aiding diagnosis and patient selection for trials.
  • Early interventions targeting lifestyle factors and amyloid in pre-dementia stages show positive preliminary results.

Conclusions:

  • Alzheimer's research is increasingly focused on the earliest, preclinical stages of the disease.
  • A combination of targeted anti-Alzheimer's therapies and lifestyle interventions is envisioned for future treatment.
  • Understanding the complex interplay of factors is crucial for developing effective strategies against Alzheimer's disease.